Intesa Sanpaolo completes share buyback totaling over €175 million

Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo Wikipedia
Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo - Wikipedia
0Comments

Intesa Sanpaolo has announced the completion of a share buyback program, executed from June 23 to June 27, 2025. The initiative, initially disclosed on May 26 and launched on June 2, was carried out in compliance with applicable regulations.

The bank confirmed that Morgan Stanley Europe SE acted as the independent third-party intermediary for this program. During the specified period, Intesa Sanpaolo acquired a total of 36,518,262 ordinary shares on the Euronext Milan market. These shares represent approximately 0.21% of the bank’s share capital.

The average purchase price per share was recorded at 4.7990 euros, resulting in a total expenditure of 175,249,832.34 euros.

This buyback is part of Intesa Sanpaolo’s strategy to manage its capital structure effectively.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.